SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
BIVI

Biovie Inc. (NASDAQ:BIVI)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$0.80-$0.11 (-12.07%)
 
Market cap
$8.58M
Insider Score
Health Score
Analyst consensus
Listed since
Sep 18, 2020
Market Cap$8.58M-38.5%
Revenue (ttm)$0
Net Income-$22.59M-22.3%
EPS-$2.90+67.4%
Shares Out10.72M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume399,581
Open$0.87
Previous Close$0.91
Day's Range$0.76 - $0.87
52-Week Range$0.75 - $3.79
Beta0.78
AnalystsBuy
Price Targetn/a
Earnings DateFeb 5, 2027
-13.17% (1D)
No price history available.

About BIVI

BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.

Address
680 West Nye Lane, Carson City, NV, 89703, US
Market Cap
9 million
Employees
13
Industrial Classification
Biotechnology

Biovie Inc. Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
27th Percentile Overall Score
BIVI InsiderScore:59 / 99

Biovie Inc. scored higher than 27% of companies evaluated by InsiderBuying, and ranked 59th out of 103 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Biovie Inc. bought $52.0K of stock across 5 purchases in the last 90 days, the largest of them $31.6K.

Stake Increase

The average purchase added about 44% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

1 of these purchases was made by someone who held no stock at all beforehand — going from nothing to a position is the strongest form of this signal.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$54.52K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Fair
From BIVI’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-12.07%
5 Days
-30.43%
1 Month
-36.51%
6 Months
-45.95%
1 Year
-38.46%

$BIVI stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in BIVI holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by BIVI's directors and management

Net Shares Purchased by Insiders−30k−15k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

BIVI Estimated quarterly lobbying spending

Source: U.S. Senate LDA

BIVI Revenue by Segment

$3.33MTotal
Clinical studies$2.24M67.36%
Clinical teams$1.02M30.75%
Chemistry, manufacturing and controls$63.00K1.89%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New BIVI patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to BIVI from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in BIVI

VXFVanguard Extended Market ETF$101.40K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from BIVI’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
60.39
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
72

News check: Multiple positive clinical data presentations for lead drug bezisterim across Long COVID and Parkinson's indications demonstrate pipeline progress.

Recent Insider Activity

Buys
6
Sells
0
Buy Value
$54.52K
Distinct Buyers
4

Insider Score Trend Over Time

-27.3 since Sep 23
0255075100Sep 23 — Insider Score 87.7Sep 24 — Insider Score 87.5Sep 25 — Insider Score 91.9Sep 26 — Insider Score 91.7Sep 27 — Insider Score 91.8Sep 28 — Insider Score 91.8Sep 29 — Insider Score 91.5Sep 30 — Insider Score 91.2Oct 1 — Insider Score 91.2Oct 2 — Insider Score 46.0Oct 3 — Insider Score 90.9Oct 4 — Insider Score 90.8Oct 5 — Insider Score 91.5Oct 6 — Insider Score 90.7Oct 7 — Insider Score 90.9Oct 8 — Insider Score 90.8Oct 9 — Insider Score 90.1Oct 10 — Insider Score 90.0Oct 11 — Insider Score 90.3Oct 12 — Insider Score 90.8Oct 13 — Insider Score 90.5Oct 14 — Insider Score 90.3Oct 15 — Insider Score 90.3Oct 16 — Insider Score 90.1Oct 17 — Insider Score 89.9Oct 18 — Insider Score 90.1Oct 19 — Insider Score 89.9Oct 20 — Insider Score 89.7Oct 21 — Insider Score 89.6Oct 22 — Insider Score 89.5Oct 23 — Insider Score 89.5Oct 24 — Insider Score 89.5Oct 25 — Insider Score 89.3Oct 26 — Insider Score 89.2Oct 27 — Insider Score 89.3Oct 28 — Insider Score 89.3Oct 29 — Insider Score 89.1Oct 30 — Insider Score 88.4Oct 31 — Insider Score 88.2Nov 1 — Insider Score 88.2Nov 2 — Insider Score 88.3Nov 3 — Insider Score 87.3Nov 4 — Insider Score 87.5Nov 5 — Insider Score 86.6Nov 6 — Insider Score 85.9Nov 7 — Insider Score 85.7Nov 8 — Insider Score 86.2Nov 9 — Insider Score 86.2Nov 10 — Insider Score 85.3Nov 11 — Insider Score 84.5Nov 12 — Insider Score 84.1Nov 13 — Insider Score 82.9Nov 14 — Insider Score 82.0Nov 15 — Insider Score 82.3Nov 16 — Insider Score 82.2Nov 17 — Insider Score 59.7Nov 18 — Insider Score 58.3Nov 19 — Insider Score 61.8Nov 20 — Insider Score 61.1Nov 21 — Insider Score 60.4Sep 23Oct 22Nov 21

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.